## Core Concept
The question pertains to the adverse effects of anti-Parkinson drugs. Parkinson's disease is a neurodegenerative disorder characterized by the depletion of dopamine in the substantia nigra, leading to motor symptoms such as tremors, rigidity, and bradykinesia. Anti-Parkinson drugs aim to either increase dopamine levels or mimic its action.

## Why the Correct Answer is Right
The correct answer, , is associated with a specific adverse effect related to its mechanism of action. This drug class includes **entacapone**, a **COMT (catechol-O-methyltransferase) inhibitor**. COMT inhibitors work by blocking the enzyme responsible for breaking down dopamine and levodopa (a dopamine precursor), thereby increasing their availability in the brain. However, one of the notable side effects of COMT inhibitors like entacapone is **diarrhea** or gastrointestinal disturbances, but more uniquely, they can cause **dyskinesia** or worsening of dyskinesia in patients on levodopa/carbidopa therapy.

## Why Each Wrong Option is Incorrect
- **Option A:** is incorrect because it does not directly relate to the known side effects associated with COMT inhibitors.
- **Option B:** is incorrect as it does not specifically point towards a drug class known for causing significant gastrointestinal or motor complications like dyskinesia.
- **Option C:** is incorrect because, although it might be related to another class of anti-Parkinson drugs, it does not directly link to the adverse effect profile characteristic of COMT inhibitors.

## Clinical Pearl / High-Yield Fact
A key point to remember is that COMT inhibitors, such as **entacapone**, are used as adjunct therapy with levodopa/carbidopa in Parkinson's disease and can lead to an increased risk of **dyskinesia**. This is a critical consideration in the management of Parkinson's disease, especially in patients with advanced disease.

## Correct Answer Line
**Correct Answer: .**